Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | DHODH | Q02127 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159020 | 0.83 | NAMPT (0.49) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7691144 | 0.81 | NPC1 (0.49) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7161060 | 0.81 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL7161066 | 0.81 | MAPT (0.59) | MAPTRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL7693917 | 0.79 | HDAC1 (0.47) | — | |
| SCHEMBL20603937 | 0.79 | CA12 (0.60) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7156921 | 0.79 | MAPT (0.46) | MAPTRAB9ASMN1; SMN2NPC1KDM4E | |
| SCHEMBL27638405 | 0.76 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL27451927 | 0.76 | MAPT (0.53) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7693197 | 0.76 | NPC1 (0.53) | MAPTRAB9ASMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6537994-B2 | For therapy and prophylaxis of metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-03-25 | — | — | US | disclosed |
| US-20020022638-A1 | Heterocyclic Beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022638-A1 | Heterocyclic Beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | CA12 4735/4885CA1 4855/4885CA2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.